-
Jiangsu Kanion Pharmaceutical Gets FDA Approval to Test KYS202004A for Psoriasis
•
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a Chinese pharmaceutical company, has announced that it has received approval from the US Food and Drug Administration (FDA) to initiate a clinical study for its pipeline candidate, KYS202004A, in the treatment of psoriasis. KYS202004A: A Dual-Targeted Fusion Protein for PsoriasisKYS202004A is an…
-
Jiangsu Kanion Pharmaceutical to Acquire Xintrum Pharmaceuticals for RMB 270 Million
•
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a China-based pharmaceutical company, has announced its intention to acquire 100% stakes in Xintrum Pharmaceuticals, Ltd, a biologic drug developer, for a consideration of RMB 270 million (USD 37.7 million). Upon completion of the deal, Xintrum will become a wholly owned subsidiary of…
-
Jiangsu Kanion Pharmaceutical Gets NMPA Go-Ahead for Psoriasis Drug Clinical Trial
•
Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a prominent pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to commence clinical studies for its investigational drug KYS202004A for the treatment of psoriasis. This Category 1 biologic is a novel, dual-targeted…
